"Linezolid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An oxazolidinone and acetamide derived ANTI-BACTERIAL AGENT and PROTEIN SYNTHESIS INHIBITOR that is used in the treatment of GRAM-POSITIVE BACTERIAL INFECTIONS of the skin and respiratory tract.
| Descriptor ID |
D000069349
|
| MeSH Number(s) |
D02.065.064.463 D02.241.081.018.110.525 D03.383.129.462.600.550
|
| Concept/Terms |
Linezolid- Linezolid
- N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
- Linezolide
U 100766- U 100766
- 100766, U
- PNU-100766
- PNU 100766
- PNU100766
- U-100766
- U100766
|
Below are MeSH descriptors whose meaning is more general than "Linezolid".
Below are MeSH descriptors whose meaning is more specific than "Linezolid".
This graph shows the total number of publications written about "Linezolid" by people in this website by year, and whether "Linezolid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 0 | 2 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Linezolid" by people in Profiles.
-
Development and validation of an LC-MS/MS multiplex assay for the quantification of bedaquiline, n-desmethyl bedaquiline, linezolid, levofloxacin, and clofazimine in dried blood spots. J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Feb 01; 1252:124470.
-
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis. PLoS One. 2024; 19(10):e0309034.
-
Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis. Antimicrob Agents Chemother. 2024 May 02; 68(5):e0158323.
-
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2024 Feb; 12(2):117-128.
-
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis. Trials. 2023 Jun 06; 24(1):382.
-
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022 12 22; 387(25):2331-2343.
-
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022 09 01; 387(9):810-823.
-
Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis. Clin Infect Dis. 2022 May 30; 74(10):1736-1747.
-
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study). Am J Respir Crit Care Med. 2022 May 15; 205(10):1214-1227.
-
Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid. BMJ Case Rep. 2021 Dec 07; 14(12).